Study on the Compensatory Mechanism of Iodine Nutrition and the Optimal Intake Level of Lactating Women

August 9, 2020 updated by: Wanqi Zhang, Tianjin Medical University
Due to the lack of direct evidence of optimal iodine intake of Chinese children, pregnant and lactating women and infants were found during the recent revision of Chinese dietary reference intakes (DRIs) of iodine in 2013 by the applicant Pro. Zhang, and no systematical research about compensatory mechanism of iodine nutrition in lactating women was found yet. Previous study funded by United Nations International Children's Emergency Fund (UNICEF) cooperated with the international experts on iodine and key project of national natural science foundation of China under the guidance of Pro. Zhang, had obtained the safe intake range of iodine from children and pregnant women, more than 10 joint papers were published, which laid the foundation of population study and international cooperation.

Study Overview

Status

Recruiting

Intervention / Treatment

Detailed Description

Studies indicate lactating women and their infants are the most vulnerable population to the adverse effects of iodine deficiency and excess, and because of the complexity of the study of lactating mothers and infants and the difficulty of sample collection, it is proposed to overcome this problem with the help of the advanced dried blood spot technique and iodine balance study method from the panel of Iodine Global Network (IGN). Investigators intend to recruit 900 late pregnant women in Tianjin, Hebei and Shandong;then establishing a dynamic cohort of breastfeeding mother-infant to 6 months after delivery to investigate the physiological compensatory mechanism of iodine nutrition in lactating women with the combination of animal experiment; On the other hand, 180 exclusively breastfeeding mother and infants within postpartum 0-6 months, will be selected to participate the iodine balance study.

Optimized method of iodine balance experiment of infants by both foreign partner and Pro. Zhang's team will be adopted to obtain the first iodine balance value of Chinese lactating women and infants,providing the direct evidence for the revision of DRIs in lactating women and infants, and guide the lactating women proper iodine supplementation to meet the requirements of both mothers and infants.

Study Type

Observational

Enrollment (Anticipated)

600

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Beijing, China
        • Recruiting
        • Institute of Nutrition and Health, Chinese Center for Disease Control and Prevention
        • Contact:
        • Contact:
      • Shandong, China
        • Recruiting
        • Shandong Institute of Endemic Disease Control and Prevention
        • Contact:
        • Contact:
      • Zurich, Switzerland
        • Recruiting
        • Swiss federal institute of Technology (ETH)
        • Contact:
        • Sub-Investigator:
          • Maria Andersson
    • Massachusetts
      • Boston, Massachusetts, United States, 02101-02117
        • Recruiting
        • Boston University School of Medicine; Iodine Global Network (IGN)
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 day to 40 years (Child, Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Women in the third trimester (18-40 years old), lactating women (38-42 weeks of gestation) and infants (0-6 months), all from Tianjin, Hebei and Shandong

Description

Inclusion Criteria:

  • Women in their third trimester:⑴Aged 18-40, who have lived in the area for 1 year;⑵Single pregnancy;⑶Those who have no special dietary habits;
  • Lactating woman:⑴Breastfeeding a child;⑵Normal thyroid function during pregnancy;⑶Term delivery (38-42 weeks of gestation);
  • Infants and young children:⑴0-6 months;⑵Breastfeeding;⑶Full term (38-42 weeks of gestation);⑷Normal birth weight (2500-4000g);⑸The thyroid-stimulating hormone (TSH) value of heel blood was normal;⑹Apgar score 8.

Exclusion Criteria:

  • Women in their third trimester:⑴Smoking or drinking;⑵Iodized drugs or contrast agents have been used in the past year;⑶A history of thyroid disease, autoimmune disease, endocrine disease, heart disease, chronic disease or family hereditary disease, etc;
  • Lactating woman:⑴A history of thyroid disease, autoimmune disease, endocrine disease, heart disease, chronic disease or family hereditary disease, etc;
  • Infants and young children:⑴Have pathological jaundice, autoimmune disease, congenital heart disease and other diseases.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Disposable random urine
Time Frame: baseline
μg/L
baseline
Venous blood
Time Frame: baseline
μg/L
baseline
Water iodine intake
Time Frame: baseline
μg/day
baseline
Salt iodine concentration
Time Frame: baseline
μg/day
baseline
Colostrum
Time Frame: 1 week
μg/L
1 week
Mother and child urine randomly at one time
Time Frame: 1 week
μg/L
1 week
Neonatal heel blood
Time Frame: 1 week
μg/L
1 week
Thyroglobulin(TG)
Time Frame: 1 week
ug/L
1 week
Thyroid-stimulating hormone
Time Frame: 1 week
mIU/L
1 week
Infant disposable random urine
Time Frame: 4 weeks
μg/L
4 weeks
Infant disposable random urine
Time Frame: 24 weeks
μg/L
24 weeks
Infant disposable random urine
Time Frame: 12 weeks
μg/L
12 weeks
24 h urine
Time Frame: 4 weeks
μg/L
4 weeks
24 h urine
Time Frame: 12 weeks
μg/L
12 weeks
24 h urine
Time Frame: 24 weeks
μg/L
24 weeks
Urinary iodine excretion
Time Frame: 4 weeks
μg/day
4 weeks
Urinary iodine excretion
Time Frame: 12 weeks
μg/day
12 weeks
Urinary iodine excretion
Time Frame: 24 weeks
μg/day
24 weeks
Milk output
Time Frame: 4 weeks
μg/day
4 weeks
Milk output
Time Frame: 12 weeks
μg/day
12 weeks
Milk output
Time Frame: 24 weeks
μg/day
24 weeks
Milk iodine excretion
Time Frame: 4 weeks
μg/day
4 weeks
Milk iodine excretion
Time Frame: 12 weeks
μg/day
12 weeks
Milk iodine excretion
Time Frame: 24 weeks
μg/day
24 weeks
Average iodine intake
Time Frame: 4 weeks
μg/day
4 weeks
Average iodine intake
Time Frame: 12 weeks
μg/day
12 weeks
Average iodine intake
Time Frame: 24 weeks
μg/day
24 weeks
Thyroid volume
Time Frame: 1 week
cm³
1 week
Thyroid volume
Time Frame: 4 weeks
cm³
4 weeks
Thyroid volume
Time Frame: 12 weeks
cm³
12 weeks
Thyroid volume
Time Frame: 24 weeks
cm³
24 weeks
Thyroid nodule
Time Frame: 1 week
cm³
1 week
Thyroid nodule
Time Frame: 4 weeks
cm³
4 weeks
Thyroid nodule
Time Frame: 12 weeks
cm³
12 weeks
Thyroid nodule
Time Frame: 24 weeks
cm³
24 weeks
Dried blood spot(DBS)
Time Frame: 3 days
μg/L
3 days
Dried blood spot(DBS)
Time Frame: 12 weeks
μg/L
12 weeks
Diet iodine intake
Time Frame: 1 week
μg/day
1 week
Fecal iodine excretion
Time Frame: 1 week
μg/day
1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: ZiYun Pan, Tianjin Medical University
  • Principal Investigator: JianQiang Lai, Institute of Nutrition and Health, Chinese Center for Disease Control and Prevention
  • Principal Investigator: XueSong Wang, Shandong Institute of Endemic Disease Control and Prevention
  • Principal Investigator: YiFan Duan, Institute of Nutrition and Health, Chinese Center for Disease Control and Prevention
  • Principal Investigator: GuiJun Tan, Tianjin Medical University
  • Principal Investigator: Wen Chen, Tianjin Medical University
  • Principal Investigator: YanTing Chen, Tianjin Medical University
  • Principal Investigator: Min Gao, Tianjin Medical University
  • Study Chair: Michael B Zimmermann, doctorate, Swiss federal institute of Technology (ETH)
  • Study Chair: Elizabeth N Pearce, doctorate, Boston University School of Medicine; Iodine Global Network (IGN)
  • Study Chair: Maria Andersson, doctorate, Swiss federal institute of Technology (ETH); Iodine Global Network (IGN)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2020

Primary Completion (Anticipated)

December 31, 2021

Study Completion (Anticipated)

December 31, 2024

Study Registration Dates

First Submitted

July 21, 2020

First Submitted That Met QC Criteria

July 27, 2020

First Posted (Actual)

July 30, 2020

Study Record Updates

Last Update Posted (Actual)

August 11, 2020

Last Update Submitted That Met QC Criteria

August 9, 2020

Last Verified

August 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Nutritional Requirements

Clinical Trials on no intervention

Subscribe